Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors

Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Stang, K. M [verfasserIn] Alite, F. [verfasserIn] Small, C. [verfasserIn] Mar, H. [verfasserIn] Adams, W. H [verfasserIn] Sethi, A. [verfasserIn] Emami, B. [verfasserIn] Harkenrider, Matthew M [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2016

Schlagwörter:	Lung cancer Central SBRT Esophagitis Esophageal toxicity

Übergeordnetes Werk:	Enthalten in: Journal of radiation oncology - Berlin : Springer, 2012, 5(2016), 4 vom: 17. Aug., Seite 371-377
Übergeordnetes Werk:	volume:5 ; year:2016 ; number:4 ; day:17 ; month:08 ; pages:371-377

Links:	Volltext

DOI / URN:	10.1007/s13566-016-0272-5

Katalog-ID:	SPR031812031

Internformat


LEADER	01000caa a22002652 4500
001	SPR031812031
003	DE-627
005	20230519141840.0
007	cr uuu---uuuuu
008	201007s2016 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s13566-016-0272-5 \|2 doi
035			\|a (DE-627)SPR031812031
035			\|a (SPR)s13566-016-0272-5-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q ASE
100	1		\|a Stang, K. M \|e verfasserin \|4 aut
245	1	0	\|a Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors
264		1	\|c 2016
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET.
650		4	\|a Lung cancer \|7 (dpeaa)DE-He213
650		4	\|a Central \|7 (dpeaa)DE-He213
650		4	\|a SBRT \|7 (dpeaa)DE-He213
650		4	\|a Esophagitis \|7 (dpeaa)DE-He213
650		4	\|a Esophageal toxicity \|7 (dpeaa)DE-He213
700	1		\|a Alite, F. \|e verfasserin \|4 aut
700	1		\|a Small, C. \|e verfasserin \|4 aut
700	1		\|a Mar, H. \|e verfasserin \|4 aut
700	1		\|a Adams, W. H \|e verfasserin \|4 aut
700	1		\|a Sethi, A. \|e verfasserin \|4 aut
700	1		\|a Emami, B. \|e verfasserin \|4 aut
700	1		\|a Harkenrider, Matthew M \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Journal of radiation oncology \|d Berlin : Springer, 2012 \|g 5(2016), 4 vom: 17. Aug., Seite 371-377 \|w (DE-627)718611233 \|w (DE-600)2660511-9 \|x 1948-7908 \|7 nnns
773	1	8	\|g volume:5 \|g year:2016 \|g number:4 \|g day:17 \|g month:08 \|g pages:371-377
856	4	0	\|u https://dx.doi.org/10.1007/s13566-016-0272-5 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2070
912			\|a GBV_ILN_2086
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2116
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2472
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 5 \|j 2016 \|e 4 \|b 17 \|c 08 \|h 371-377

Indexfelder

author_variant	k m s km kms f a fa c s cs h m hm w h a wh wha a s as b e be m m h mm mmh
matchkey_str	article:19487908:2016----::oepeitroeohgatxctwtseetcibdrdainh
hierarchy_sort_str	2016
publishDate	2016
allfields	10.1007/s13566-016-0272-5 doi (DE-627)SPR031812031 (SPR)s13566-016-0272-5-e DE-627 ger DE-627 rakwb eng 610 ASE Stang, K. M verfasserin aut Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET. Lung cancer (dpeaa)DE-He213 Central (dpeaa)DE-He213 SBRT (dpeaa)DE-He213 Esophagitis (dpeaa)DE-He213 Esophageal toxicity (dpeaa)DE-He213 Alite, F. verfasserin aut Small, C. verfasserin aut Mar, H. verfasserin aut Adams, W. H verfasserin aut Sethi, A. verfasserin aut Emami, B. verfasserin aut Harkenrider, Matthew M verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 5(2016), 4 vom: 17. Aug., Seite 371-377 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:5 year:2016 number:4 day:17 month:08 pages:371-377 https://dx.doi.org/10.1007/s13566-016-0272-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 5 2016 4 17 08 371-377
spelling	10.1007/s13566-016-0272-5 doi (DE-627)SPR031812031 (SPR)s13566-016-0272-5-e DE-627 ger DE-627 rakwb eng 610 ASE Stang, K. M verfasserin aut Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET. Lung cancer (dpeaa)DE-He213 Central (dpeaa)DE-He213 SBRT (dpeaa)DE-He213 Esophagitis (dpeaa)DE-He213 Esophageal toxicity (dpeaa)DE-He213 Alite, F. verfasserin aut Small, C. verfasserin aut Mar, H. verfasserin aut Adams, W. H verfasserin aut Sethi, A. verfasserin aut Emami, B. verfasserin aut Harkenrider, Matthew M verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 5(2016), 4 vom: 17. Aug., Seite 371-377 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:5 year:2016 number:4 day:17 month:08 pages:371-377 https://dx.doi.org/10.1007/s13566-016-0272-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 5 2016 4 17 08 371-377
allfields_unstemmed	10.1007/s13566-016-0272-5 doi (DE-627)SPR031812031 (SPR)s13566-016-0272-5-e DE-627 ger DE-627 rakwb eng 610 ASE Stang, K. M verfasserin aut Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET. Lung cancer (dpeaa)DE-He213 Central (dpeaa)DE-He213 SBRT (dpeaa)DE-He213 Esophagitis (dpeaa)DE-He213 Esophageal toxicity (dpeaa)DE-He213 Alite, F. verfasserin aut Small, C. verfasserin aut Mar, H. verfasserin aut Adams, W. H verfasserin aut Sethi, A. verfasserin aut Emami, B. verfasserin aut Harkenrider, Matthew M verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 5(2016), 4 vom: 17. Aug., Seite 371-377 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:5 year:2016 number:4 day:17 month:08 pages:371-377 https://dx.doi.org/10.1007/s13566-016-0272-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 5 2016 4 17 08 371-377
allfieldsGer	10.1007/s13566-016-0272-5 doi (DE-627)SPR031812031 (SPR)s13566-016-0272-5-e DE-627 ger DE-627 rakwb eng 610 ASE Stang, K. M verfasserin aut Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET. Lung cancer (dpeaa)DE-He213 Central (dpeaa)DE-He213 SBRT (dpeaa)DE-He213 Esophagitis (dpeaa)DE-He213 Esophageal toxicity (dpeaa)DE-He213 Alite, F. verfasserin aut Small, C. verfasserin aut Mar, H. verfasserin aut Adams, W. H verfasserin aut Sethi, A. verfasserin aut Emami, B. verfasserin aut Harkenrider, Matthew M verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 5(2016), 4 vom: 17. Aug., Seite 371-377 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:5 year:2016 number:4 day:17 month:08 pages:371-377 https://dx.doi.org/10.1007/s13566-016-0272-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 5 2016 4 17 08 371-377
allfieldsSound	10.1007/s13566-016-0272-5 doi (DE-627)SPR031812031 (SPR)s13566-016-0272-5-e DE-627 ger DE-627 rakwb eng 610 ASE Stang, K. M verfasserin aut Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET. Lung cancer (dpeaa)DE-He213 Central (dpeaa)DE-He213 SBRT (dpeaa)DE-He213 Esophagitis (dpeaa)DE-He213 Esophageal toxicity (dpeaa)DE-He213 Alite, F. verfasserin aut Small, C. verfasserin aut Mar, H. verfasserin aut Adams, W. H verfasserin aut Sethi, A. verfasserin aut Emami, B. verfasserin aut Harkenrider, Matthew M verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 5(2016), 4 vom: 17. Aug., Seite 371-377 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:5 year:2016 number:4 day:17 month:08 pages:371-377 https://dx.doi.org/10.1007/s13566-016-0272-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 5 2016 4 17 08 371-377
language	English
source	Enthalten in Journal of radiation oncology 5(2016), 4 vom: 17. Aug., Seite 371-377 volume:5 year:2016 number:4 day:17 month:08 pages:371-377
sourceStr	Enthalten in Journal of radiation oncology 5(2016), 4 vom: 17. Aug., Seite 371-377 volume:5 year:2016 number:4 day:17 month:08 pages:371-377
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Lung cancer Central SBRT Esophagitis Esophageal toxicity
dewey-raw	610
isfreeaccess_bool	false
container_title	Journal of radiation oncology
authorswithroles_txt_mv	Stang, K. M @@aut@@ Alite, F. @@aut@@ Small, C. @@aut@@ Mar, H. @@aut@@ Adams, W. H @@aut@@ Sethi, A. @@aut@@ Emami, B. @@aut@@ Harkenrider, Matthew M @@aut@@
publishDateDaySort_date	2016-08-17T00:00:00Z
hierarchy_top_id	718611233
dewey-sort	3610
id	SPR031812031
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR031812031</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519141840.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2016 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13566-016-0272-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR031812031</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13566-016-0272-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Stang, K. M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lung cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Central</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">SBRT</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Esophagitis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Esophageal toxicity</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alite, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Small, C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mar, H.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Adams, W. H</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sethi, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Emami, B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Harkenrider, Matthew M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of radiation oncology</subfield><subfield code="d">Berlin : Springer, 2012</subfield><subfield code="g">5(2016), 4 vom: 17. Aug., Seite 371-377</subfield><subfield code="w">(DE-627)718611233</subfield><subfield code="w">(DE-600)2660511-9</subfield><subfield code="x">1948-7908</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:5</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:4</subfield><subfield code="g">day:17</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:371-377</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13566-016-0272-5</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">5</subfield><subfield code="j">2016</subfield><subfield code="e">4</subfield><subfield code="b">17</subfield><subfield code="c">08</subfield><subfield code="h">371-377</subfield></datafield></record></collection>
author	Stang, K. M
spellingShingle	Stang, K. M ddc 610 misc Lung cancer misc Central misc SBRT misc Esophagitis misc Esophageal toxicity Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors
authorStr	Stang, K. M
ppnlink_with_tag_str_mv	@@773@@(DE-627)718611233
format	electronic Article
dewey-ones	610 - Medicine & health
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1948-7908
topic_title	610 ASE Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors Lung cancer (dpeaa)DE-He213 Central (dpeaa)DE-He213 SBRT (dpeaa)DE-He213 Esophagitis (dpeaa)DE-He213 Esophageal toxicity (dpeaa)DE-He213
topic	ddc 610 misc Lung cancer misc Central misc SBRT misc Esophagitis misc Esophageal toxicity
topic_unstemmed	ddc 610 misc Lung cancer misc Central misc SBRT misc Esophagitis misc Esophageal toxicity
topic_browse	ddc 610 misc Lung cancer misc Central misc SBRT misc Esophagitis misc Esophageal toxicity
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Journal of radiation oncology
hierarchy_parent_id	718611233
dewey-tens	610 - Medicine & health
hierarchy_top_title	Journal of radiation oncology
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)718611233 (DE-600)2660511-9
title	Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors
ctrlnum	(DE-627)SPR031812031 (SPR)s13566-016-0272-5-e
title_full	Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors
author_sort	Stang, K. M
journal	Journal of radiation oncology
journalStr	Journal of radiation oncology
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	2016
contenttype_str_mv	txt
container_start_page	371
author_browse	Stang, K. M Alite, F. Small, C. Mar, H. Adams, W. H Sethi, A. Emami, B. Harkenrider, Matthew M
container_volume	5
class	610 ASE
format_se	Elektronische Aufsätze
author-letter	Stang, K. M
doi_str_mv	10.1007/s13566-016-0272-5
dewey-full	610
author2-role	verfasserin
title_sort	novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors
title_auth	Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors
abstract	Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET.
abstractGer	Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET.
abstract_unstemmed	Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700
container_issue	4
title_short	Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors
url	https://dx.doi.org/10.1007/s13566-016-0272-5
remote_bool	true
author2	Alite, F. Small, C. Mar, H. Adams, W. H Sethi, A. Emami, B. Harkenrider, Matthew M
author2Str	Alite, F. Small, C. Mar, H. Adams, W. H Sethi, A. Emami, B. Harkenrider, Matthew M
ppnlink	718611233
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1007/s13566-016-0272-5
up_date	2024-07-04T01:20:56.876Z
_version_	1803609499899002880
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR031812031</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519141840.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2016 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13566-016-0272-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR031812031</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13566-016-0272-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Stang, K. M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lung cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Central</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">SBRT</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Esophagitis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Esophageal toxicity</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alite, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Small, C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mar, H.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Adams, W. H</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sethi, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Emami, B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Harkenrider, Matthew M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of radiation oncology</subfield><subfield code="d">Berlin : Springer, 2012</subfield><subfield code="g">5(2016), 4 vom: 17. Aug., Seite 371-377</subfield><subfield code="w">(DE-627)718611233</subfield><subfield code="w">(DE-600)2660511-9</subfield><subfield code="x">1948-7908</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:5</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:4</subfield><subfield code="g">day:17</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:371-377</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13566-016-0272-5</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">5</subfield><subfield code="j">2016</subfield><subfield code="e">4</subfield><subfield code="b">17</subfield><subfield code="c">08</subfield><subfield code="h">371-377</subfield></datafield></record></collection>
score	7.3992853

Nicht das Richtige dabei?

Schreiben Sie uns!

Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?